Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study
- PMID: 26824711
- DOI: 10.1148/radiol.2016151243
Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study
Abstract
Purpose To compare the long-term therapeutic outcomes of radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) in subcapsular versus nonsubcapsular locations by using propensity score matching. Materials and Methods RF ablation for subcapsular HCC is controversial because of a high risk of incomplete ablation or major complications. This retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. Between April 2006 and December 2011, 508 consecutive patients (396 men, 112 women; age range, 30-80 years) with a single HCC (Barcelona Clinic Liver Cancer stage 0 or A) underwent ultrasonography-guided percutaneous RF ablation as a first-line treatment. The patients were divided into two groups according to tumor location: subcapsular (n = 227) and nonsubcapsular (n = 281). Subcapsular HCC was defined as an index tumor located within 0.1 cm of the liver capsule. The association of subcapsular location and therapeutic outcomes of RF ablation was evaluated, including (a) local tumor progression (LTP) by using a competing risk regression model and (b) overall survival (OS) by using a Cox proportional hazards model according to propensity score matched data. The major complication rates from both overall data and matched data were assessed. Results Matching yielded 163 matched pairs of patients. In the two matched groups, cumulative LTP rates were 18.8% and 20.9% at 3 and 5 years, respectively, in the subcapsular group and 13.2% and 16.0% in the nonsubcapsular group. Corresponding OS rates were 90.7% for 3 years and 83.2% for 5 years in the subcapsular group and 91.4% and 79.1%, respectively, in the nonsubcapsular group. Hazard ratios (HRs) for LTP (HR = 1.37, P = .244) and OS (HR = 0.86, P = .604) were not significantly different between the two matched groups. Additionally, differences in major complication rates were not significant between groups for the two sets of data (P > .05). Conclusion The differences in LTP, OS, and major complication rates of RF ablation for HCC were not significant between subcapsular and nonsubcapsular groups. (©) RSNA, 2016.
Similar articles
-
Radiofrequency ablation of subcapsular versus nonsubcapsular hepatocellular carcinomas ≤ 3 cm: analysis of long-term outcomes from two large-volume liver centers.Eur Radiol. 2024 Mar;34(3):1578-1586. doi: 10.1007/s00330-023-10165-6. Epub 2023 Aug 30. Eur Radiol. 2024. PMID: 37646813
-
Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness.Radiology. 2008 Aug;248(2):670-9. doi: 10.1148/radiol.2482071690. Epub 2008 Jun 2. Radiology. 2008. PMID: 18519740
-
Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection--Propensity Score Analyses of Long-term Outcomes.Radiology. 2015 Jun;275(3):908-19. doi: 10.1148/radiol.15141483. Epub 2015 Feb 16. Radiology. 2015. PMID: 25688888
-
Small hepatocellular carcinomas: ultrasonography guided percutaneous radiofrequency ablation.Abdom Imaging. 2013 Feb;38(1):98-111. doi: 10.1007/s00261-012-9883-5. Abdom Imaging. 2013. PMID: 22467060 Review.
-
Open Liver Resection, Laparoscopic Liver Resection, and Percutaneous Thermal Ablation for Patients with Solitary Small Hepatocellular Carcinoma (≤30 mm): Review of the Literature and Proposal for a Therapeutic Strategy.Dig Surg. 2018;35(4):359-371. doi: 10.1159/000489836. Epub 2018 Jun 11. Dig Surg. 2018. PMID: 29890512 Review.
Cited by
-
Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.Saudi J Gastroenterol. 2020 Oct;26(Suppl 1):S1-S40. doi: 10.4103/sjg.SJG_477_20. Saudi J Gastroenterol. 2020. PMID: 33078723 Free PMC article. No abstract available.
-
Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma.Cardiovasc Intervent Radiol. 2022 Dec;45(12):1812-1821. doi: 10.1007/s00270-022-03210-2. Epub 2022 Jul 28. Cardiovasc Intervent Radiol. 2022. PMID: 35902397
-
Risk Group Stratification for Recurrence-Free Survival and Early Tumor Recurrence after Radiofrequency Ablation for Hepatocellular Carcinoma.Cancers (Basel). 2023 Jan 22;15(3):687. doi: 10.3390/cancers15030687. Cancers (Basel). 2023. PMID: 36765645 Free PMC article.
-
Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure.Eur Radiol. 2019 May;29(5):2706-2715. doi: 10.1007/s00330-018-5868-2. Epub 2018 Nov 30. Eur Radiol. 2019. PMID: 30506222
-
Local anaesthesia vs. general anaesthesia for percutaneous microwave ablation in hepatocellular carcinoma: efficacy, safety, and cost analysis.Front Oncol. 2023 Sep 12;13:1186133. doi: 10.3389/fonc.2023.1186133. eCollection 2023. Front Oncol. 2023. PMID: 37771440 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous